Infinity Bio Taps New CEO to Scale Breakthrough Immune-Mapping Tech

BALTIMORE, MD – March 18, 2026 – Biotechnology innovator Infinity Bio has appointed seasoned life sciences executive Brian McKelligon as its new Chief Executive Officer, a strategic move signaling a major push toward commercializing its revolutionary immune-profiling technology. McKelligon, who brings a formidable track record of scaling cutting-edge platforms, is tasked with steering the company through its next growth phase, accelerating the global adoption of its proprietary MIPSA technology.

Infinity Bio is at the forefront of decoding the "antibody reactome"—the complete history of a person's immune responses. This vast, complex dataset, stored within our antibodies, holds the key to understanding an individual's past infections, environmental exposures, and the triggers for autoimmune diseases. By making sense of this history, the company aims to unlock a new era of precision diagnostics and therapies.

The appointment comes at a pivotal moment for the Baltimore-based firm. “Infinity Bio is at an exciting moment in its evolution. With a world-class team, breakthrough MIPSA technology, and significant momentum from recent financings, product launches, and strong customer traction, the company is well positioned for its next phase of growth,” said Matt Hellauer, Managing Partner at PTX Capital, a key investor. McKelligon’s leadership is seen as the final piece of the puzzle to capitalize on this momentum.

An Architect of Commercial Success

Brian McKelligon is no stranger to transforming promising technology into market-leading platforms. His career is a blueprint for commercializing complex scientific tools. Most recently, as CEO of Akoya Biosciences, he orchestrated the company's rapid ascent in the spatial biology sector. Under his leadership, Akoya acquired the Phenoptics portfolio from PerkinElmer, successfully launched its CODEX system, and completed a public offering that saw its inclusion in the Russell 3000 Index in 2021. His tenure was also marked by forging crucial strategic partnerships with industry giants like Nikon, Zeiss, and AstraZeneca.

Before Akoya, McKelligon held leadership roles at other pioneering companies that have since become household names in life sciences. He was Vice President at 10x Genomics and previously held positions at Ion Torrent Systems, both companies that fundamentally changed the landscape of genomics. This history of identifying and scaling disruptive technologies makes him a uniquely qualified choice for Infinity Bio.

Investors are betting that he can replicate this success. “Brian brings a proven track record of translating cutting-edge technologies into widely adopted platforms,” noted Malek Fahem, Chief Scientist at Illumina Ventures. “His leadership will be instrumental in driving MIPSA toward global adoption as an essential tool for translational and discovery science.”

Decoding the Immune System with MIPSA

At the heart of Infinity Bio's strategy is its core technology, MIPSA (Molecular Indexing of Proteins by Self-Assembly). Developed in the Larman Laboratory of Precision Immunology at Johns Hopkins University, MIPSA provides an unprecedented high-resolution map of the antibody reactome. While the immune system’s complexity has long been a barrier to comprehensive analysis, MIPSA offers a powerful solution.

The platform leverages the power of DNA synthesis and sequencing to analyze millions of antibody-antigen interactions simultaneously. It screens a patient's blood sample against vast, proteomic-scale libraries that represent a wide array of potential immune triggers. These libraries include:

• VirSIGHT™: Containing proteins from all known human viruses.
• HuSIGHT™: Comprised of the entire human proteome to detect autoantibodies, the hallmarks of autoimmune disease.
• EnviroSIGHT™: Featuring allergens, common environmental antigens, and non-viral microbes.

“Our MIPSA platform leverages the power of DNA synthesis and sequencing to read the antibody reactome at unmatched breadth and depth, empowering researchers worldwide to unlock insights that were previously out of reach,” McKelligon stated upon his appointment.

By cross-referencing an individual's antibody profile against these libraries, MIPSA can create a detailed personal history of immune activity. This allows researchers to connect specific immune responses to clinical outcomes on a population scale, uncovering functional links between environment, immunity, and disease that were previously invisible.

Redefining Precision Medicine

The implications of this technology extend far beyond the research lab. By providing a clear, data-driven picture of an individual's immune status, Infinity Bio is paving the way for a more personalized and proactive approach to healthcare. The ability to comprehensively map the antibody reactome has the potential to revolutionize diagnostics and treatment across numerous fields.

In autoimmune disorders like lupus or rheumatoid arthritis, MIPSA could identify the specific self-antigens being targeted by the immune system long before symptoms become severe, enabling earlier intervention. For infectious diseases, it could provide a complete history of a patient's viral encounters, informing vaccine strategies and public health surveillance. In oncology, understanding a patient's immune response to a tumor is critical for the success of immunotherapies, and MIPSA offers a tool to gain those insights.

The technology also holds promise for tackling allergies, neurodegenerative disorders, and even the aging process itself, all of which have significant immunological components. As the platform gains traction in research and clinical settings, it could shift the medical paradigm from treating established diseases to predicting risk and preventing illness based on an individual's unique immune profile. With McKelligon now leading the charge, Infinity Bio is poised to move this powerful vision from a scientific possibility to a clinical reality.